1. Home
  2. EYPT vs ABEO Comparison

EYPT vs ABEO Comparison

Compare EYPT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EYPT

EyePoint Pharmaceuticals Inc.

N/A

Current Price

$0.23

Market Cap

273.3M

Sector

Industrials

ML Signal

N/A

Logo Abeona Therapeutics Inc.

ABEO

Abeona Therapeutics Inc.

N/A

Current Price

$2.42

Market Cap

282.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EYPT
ABEO
Founded
1987
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
273.3M
282.5M
IPO Year
2005
2005

Fundamental Metrics

Financial Performance
Metric
EYPT
ABEO
Price
$0.23
$2.42
Analyst Decision
Hold
Strong Buy
Analyst Count
13
7
Target Price
$8.31
★ $15.56
AVG Volume (30 Days)
★ 5.8M
2.2M
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 165.16
EPS
N/A
★ N/A
Revenue
★ $7,539,000.00
$2,998,000.00
Revenue This Year
N/A
$675.42
Revenue Next Year
N/A
$126.99
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 258.18
52 Week Low
$0.26
$2.09
52 Week High
$19.11
$7.65

Technical Indicators

Market Signals
Indicator
EYPT
ABEO
Relative Strength Index (RSI) 16.61 27.49
Support Level N/A $2.09
Resistance Level $3.57 $5.77
Average True Range (ATR) 0.04 0.32
MACD 0.13 -0.03
Stochastic Oscillator 2.11 15.88

Price Performance

Historical Comparison
EYPT
ABEO

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Share on Social Networks: